Bio-Path Holdings, Inc. Expands DNAbilize® Technology to Obesity Treatment, Reveals Third Quarter Financial Results
Bio-Path Holdings reports Q3 2024 results, initiating obesity program, advancing oncology trials, and closing a $4M private placement.Quiver AI SummaryBio-Path Holdings, Inc. has expanded its DNAbilize®...
Acute Myeloid Leukemia Market Size Expected to Reach $2.97 Billion By 2029 as Clinical Trials Increase
EQNX::TICKER_START (NYSE:ATNM),(NASDAQ:BPTH),(NASDAQ:LGVN),(NASDAQ:SLS),(NYSE:BMY) EQNX::TICKER_END